Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Oct 22;32(11):743.
doi: 10.1007/s00520-024-08929-x.

Enhancing patient-centered care: a randomized study on G-CSF administration preferences in chemotherapy-induced neutropenia

Nathaniel Scher  1   2 , Hanène Boudabous  3   4 , Judith Partouche  5   6 , Saeedeh Rezaee-Vessal  5   6 , Paul Ihout  3   4 , Claudia Rizzo  3   4 , Hanah Lamallem  3   4 , Olivier Bauduceau  3   4 , Ilan Darmon  3   4 , Marc Bollet  3   4 , Clément Draghi  3   4 , Alain Toledano  3   4   7
Affiliations
Randomized Controlled Trial

Enhancing patient-centered care: a randomized study on G-CSF administration preferences in chemotherapy-induced neutropenia

Nathaniel Scher et al. Support Care Cancer. .

Abstract

Purpose: Chemotherapy-induced neutropenia poses a significant risk to cancer patients, with pegfilgrastim being commonly used for its prevention. While pegfilgrastim can be administered via prefilled syringe or pen device, patient preferences and experiences with these delivery methods remain unclear.

Methods: We conducted a prospective, open-label, randomized, observational trial (NCT05910164) at the Rafael Institute, France, comparing patient preferences for pegfilgrastim administration using a prefilled syringe versus a prefilled pen device. Patients undergoing chemotherapy and requiring pegfilgrastim were enrolled and randomized 1:1 to receive either syringe or pen first, with crossover administration. Questionnaires assessed patient preferences, learning experiences, autonomy, pain levels, emotional responses, satisfaction with nursing care, and empowerment.

Results: Among 150 randomized patients (mean age 58 years; 69% female), both groups showed a preference for the pen device, with significantly higher mean scores favoring pen administration (4.94 ± 1.70 vs. 4.27 ± 1.84; p = 0.00106). Patients reported significantly lower perceived pain with pen administration and stronger positive emotions compared to syringe use. Satisfaction with nursing care was higher with syringe use. Empowerment levels were similar across groups but significantly stronger when using the pen in complete autonomy.

Conclusion: A preference for pegfilgrastim administration via the pen device was observed, though this may have been influenced by the administration sequence and the absence of syringe self-administration. The insights gained can help inform clinical decision-making and improve patient-centered care in managing chemotherapy-induced neutropenia.

Trial registration: NCT05910164 on June 15, 2023.

Keywords: Cancer; Chemotherapy-induced febrile neutropenia; Patient empowerment; Patient outcome assessment; Patient preference; Patient-centered care.

PubMed Disclaimer

References

    1. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100(2):228–237. https://doi.org/10.1002/cncr.11882 - DOI - PubMed
    1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266. https://doi.org/10.1002/cncr.21847 - DOI - PubMed
    1. Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404. https://doi.org/10.1186/1471-2407-11-404 - DOI - PubMed - PMC
    1. Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R (2013) Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colonys timulating factors (G-CSF). BMC Cancer 13:11. https://doi.org/10.1186/1471-2407-13-11 - DOI - PubMed - PMC
    1. Crawford J, Caserta C, Roila F, ESMO Guidelines Working Group (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21(Suppl 5):v248-51. https://doi.org/10.1093/annonc/mdq195 - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources